Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PubMed (original) (raw)

Review

Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Avneet Singh et al. Nutrients. 2024.

Abstract

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a common cause of chronic liver disease globally, with prevalence rapidly increasing in parallel with rising rates of obesity and metabolic syndrome. MASLD is defined by the presence of excess fat in the liver, which may induce inflammatory changes and subsequent fibrosis in high-risk patients. Though MASLD occurs frequently, there is still no approved pharmacological treatment, and the mainstay of therapy remains lifestyle modification via dietary changes, enhancement of physical activity, and management of metabolic comorbidities. Most nutrition research and clinical guidance in this disease centers on the reduction in fructose and saturated fat in the diet, although the emerging literature suggests that protein supplementation is important and implicates muscle mass and sarcopenia in disease-related outcomes. This review will assess the current data on these topics, with the goal of defining best practices and identifying research gaps in care.

Keywords: fatty liver; hepatic steatosis; malnutrition; metabolic dysfunction-associated steatotic liver disease; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

Avneet Singh, Adam Buckholz and Sonal Kumar declare no relevant conflicts of interest. Carolyn Newberry received a speaking honorarium from Baxter International and consulting fees from Nestle Health Sciences.

Figures

Figure 1

Figure 1

Relationship of pathophysiologic pathways in sarcopenia and MASLD.

References

    1. Younossi Z.M., Stepanova M., Younossi Y., Golabi P., Mishra A., Rafiq N., Henry L. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020;69:564–568. doi: 10.1136/gutjnl-2019-318813. - DOI - PubMed
    1. Chalasani N., Younossi Z., LaVine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. doi: 10.1002/hep.29367. - DOI - PubMed
    1. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F., Romero D., Abdelmalek M.F., Anstee Q.M., Arab J.P., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966–1986. doi: 10.1097/HEP.0000000000000520. - DOI - PMC - PubMed
    1. Le M.H., Yeo Y.H., Zou B., Barnet S., Henry L., Cheung R., Nguyen M.H. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin. Mol. Hepatol. 2022;28:841–850. doi: 10.3350/cmh.2022.0239. - DOI - PMC - PubMed
    1. Huang T., Behary J., Zekry A. Non-alcoholic fatty liver disease: A review of epidemiology, risk factors, diagnosis and management. Intern. Med. J. 2020;50:1038–1047. doi: 10.1111/imj.14709. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources